TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT03038802: A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection

Sponsor: Vaxine Pty Ltd · Phase: PHASE1/PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 40 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,521,990

Rescue Site Savings

+$4,973,010

Unlock Full NCT03038802 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03038802 Rescue Dossier →